Inclusion Criteria:  Subjects are eligible to be included in the study only if ALL of the following criteria apply:  HIV-1 sero-positive, with documented HIV-1 infection by official, signed, written history (e.g., a laboratory report). Male with body weight ≥ 50 kg or female with body weight ≥ 45 kg, aged 18 years or older. Have been receiving ART, defined as at least (≧) 2 nucleoside/ nucleotide reverse transcriptase inhibitors (NRTI) plus one non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI, either boosted or un-boosted), integrase strand transfer inhibitor (INSTI) or entry inhibitor (EI) for more than 1 years by screening visit 1 (SV1). Have more than 2 different alternative options of optimized ART regimen. HIV-1 plasma viral load (VL) level below 50 RNA copies/mL for at least (≧) 12 months prior to SV2, with at least 2 viral load measurements within 12 months. HIV-1 Plasma VL should also be below 50 RNA copies/mL at SV2. HIV total DNA ≥ 300 copies per million CD4+ T cells at SV1. With 2 records of CD4+ T cell count ≧ 350 cells/mm3 that were measured at least 12 weeks apart during the 12 months before SV2. With a CD4+ T cell count ≧ 350 cells/mm3 obtained at SV2. No breastfeeding or pregnancy for women. Both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (eg, barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectable, combinational oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test at SV2.  Laboratory values at SV2 should meet:  Platelets ≥ 75 × 109/L Absolute neutrophil count ≥ 1.5×109/L Hemoglobin ≥ 10 g/dL Serum alanine transaminase (serum glutamic-pyruvic transaminase/alanine transaminase [GPT/ALT]) or serum aspartate transaminase (serum glutamic-oxaloacetic transaminase/aspartate transaminase [GOT/AST]) ≤ 2.5x upper limit of normal (ULN) Bilirubin (total) < 1.5 x ULN Serum creatinine ≤ 1.5 x ULN Subjects must sign the informed consent before undergoing any study procedures.  Exclusion Criteria:  Subjects meeting ANY of the following criteria will be excluded from the study:  Subjects with active systemic infections, except for HIV-1, that the investigator feels the infections may confound evaluation and treatment for HIV-1. Any acquired AIDS-defining illness such as non-Hodgkin's lymphoma or Kaposi's sarcoma according to the U.S. Centers for Disease Control and Prevention Classification System for HIV-1 Infection within the past 12 months before SV2. Any documented CD4+ T cell count < 200 cells/mm3 within the past 12 weeks before SV2. Any exposure to a monoclonal antibody within 12 weeks prior to the first dose of study drug. Any significant diseases (other than HIV-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined from the screening, medical history, and/or physical examination that, in the Investigator's opinion, would preclude the subject from good compliance and well participation in this study. Current receiving treatment regimen for hepatitis B and hepatitis C or latent tuberculosis. History of anaphylaxis to any monoclonal antibodies or HDAC inhibitor agents. Received blood transfusion or hematopoietic growth factor treatment within 3 months before the screening visit (SV2), or received a compound with HDAC inhibitor activity (such as valproic acid) within 1 month before the SV1. Potential participants can be considered after the indicated wash-out periods of these drugs/agents. Any vaccination within 8 weeks prior to V1. Use of immunomodulators (including interleukins, interferon, cyclosporine, continual use of systemic corticosteroid for more than 30 days), HIV vaccine, or systemic chemotherapy within 180 days prior to V1. Any alcohol or illicit drug use, according to the Investigator's opinion, will interfere with subject's ability to comply with the dosing, visit schedules and protocol evaluations. More than one change of ART regimen because of the inability to achieve or maintain suppression of viral replication to an HIV-1 RNA level < 200 copies/mL within the past 12 months before SV2. Receipt of any other investigational study agent(s) within 90 days before SV2. A history of clinically significant cardiac diseases, including symptomatic or asymptomatic arrhythmias, syncopal episodes, or hyperactive/venous thrombosis events 6 months before SV1, such as cerebrovascular accidents (including temporary ischemic attack), deep venous thrombosis or pulmonary embolism. Experienced urticaria in the 6 months before the screening visit (SV2) or had ongoing or unresolved skin problems with rash-like symptoms (eg. eczema, atopic dermatitis, urticaria) at SV2. Diabetes.